Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort).

Torti C, Raffetti E, Donato F, Castelli F, Maggiolo F, Angarano G, Mazzotta F, Gori A, Sighinolfi L, Pan A, Cauda R, Scalzini A, Quiros-Roldan E, Nasta P, Gregis G, Benatti S, Digiambenedetto S, Ladisa N, Giralda M, Saracino A, Castelnuovo F, Di Pietro M, Lo Caputo S, Lapadula G, Costarelli S, Lorenzotti S, Mazzini N, Paraninfo G, Casari S, Focà E, Pezzoli C, Fabbiani M, Monno L, Pierotti P, Ble C, Leone S, Postorino MC, Fornabaio C, Zacchi F, Zoncada A, Carosi G.

Int J Epidemiol. 2017 Apr 1;46(2):e12. doi: 10.1093/ije/dyv192. No abstract available.

PMID:
26445966
2.

Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study.

Raffetti E, Albini L, Gotti D, Segala D, Maggiolo F, di Filippo E, Saracino A, Ladisa N, Lapadula G, Fornabaio C, Castelnuovo F, Casari S, Fabbiani M, Pierotti P, Donato F, Quiros-Roldan E; MASTER Cohort.

BMC Public Health. 2015 Mar 12;15:235. doi: 10.1186/s12889-015-1565-0.

3.

HBV whole-genome mutation profile in HIV-1/HBV coinfected patients in a long-term follow-up study.

Taffon S, Genovese D, Blasi M, Pierotti P, Degli Esposti A, Catone S, Chionne P, Pulimanti B, Candido A, Dettori S, Tosti ME, Argentini C, Mazzotta F, Rapicetta M.

Infection. 2014 Aug;42(4):675-87. doi: 10.1007/s15010-014-0616-2. Epub 2014 Apr 4.

PMID:
24700252
4.

Mycobacterium yongonense in pulmonary disease, Italy.

Tortoli E, Mariottini A, Pierotti P, Simonetti TM, Rossolini GM.

Emerg Infect Dis. 2013 Nov;19(11):1902-4. doi: 10.3201/eid1911.130911. No abstract available.

5.

Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study.

Gillio-Tos A, De Marco L, Carozzi FM, Del Mistro A, Girlando S, Burroni E, Frayle-Salamanca H, Giorgi Rossi P, Pierotti P, Ronco G; New Technologies for Cervical Cancer Screening Working Group.

J Clin Microbiol. 2013 Sep;51(9):2901-7. doi: 10.1128/JCM.01047-13. Epub 2013 Jun 26.

6.

Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC trial.

Baussano I, Franceschi S, Gillio-Tos A, Carozzi F, Confortini M, Dalla Palma P, De Lillo M, Del Mistro A, De Marco L, Naldoni C, Pierotti P, Schincaglia P, Segnan N, Zorzi M, Giorgi-Rossi P, Ronco G.

BMC Infect Dis. 2013 May 24;13:238. doi: 10.1186/1471-2334-13-238.

7.

A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18-26 years.

Giambi C, Donati S, Carozzi F, Salmaso S, Declich S, Atti ML, Ronco G, Alibrandi MP, Brezzi S, Collina N, Franchi D, Lattanzi A, Minna MC, Nannini R, Barretta E, Burroni E, Gillio-Tos A, Macallini V, Pierotti P, Bella A.

BMC Infect Dis. 2013 Feb 7;13:74. doi: 10.1186/1471-2334-13-74.

8.

The virtual slide in the promotion of cytologic and hystologic quality in oncologic screenings.

Bondi A, Pierotti P, Crucitti P, Lega S.

Ann Ist Super Sanita. 2010;46(2):144-50. doi: DOI: 10.4415/ANN_10_02_07.

9.

TLR activation pathways in HIV-1-exposed seronegative individuals.

Biasin M, Piacentini L, Lo Caputo S, Naddeo V, Pierotti P, Borelli M, Trabattoni D, Mazzotta F, Shearer GM, Clerici M.

J Immunol. 2010 Mar 1;184(5):2710-7. doi: 10.4049/jimmunol.0902463. Epub 2010 Feb 1.

10.

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.

Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J; New Technologies for Cervical Cancer screening (NTCC) Working Group.

Lancet Oncol. 2010 Mar;11(3):249-57. doi: 10.1016/S1470-2045(09)70360-2. Epub 2010 Jan 18.

PMID:
20089449
11.

Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial.

Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, Ghiringhello B, Giorgi-Rossi P, Minucci D, Parisio F, Pojer A, Schiboni ML, Sintoni C, Zorzi M, Segnan N, Confortini M.

BMJ. 2007 Jul 7;335(7609):28. Epub 2007 May 21.

12.

CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.

Torti C, Lapadula G, Barreiro P, Soriano V, Mandalia S, De Silvestri A, Suter F, Maggiolo F, Antinori A, Antonucci F, Maserati R, El Hamad I, Pierotti P, Sighinolfi L, Migliorino G, Ladisa N, Carosi G; Italian MASTER Cohort.

J Antimicrob Chemother. 2007 Jun;59(6):1141-7. Epub 2007 Apr 13.

PMID:
17434879
13.

Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy.

Quiros-Roldan E, Torti C, Lapadula G, Ladisa N, Micheli V, Patroni A, Cusato M, Pierotti P, Tirelli V, Uccelli MC, Di Giambenedetto S, Castelnuovo F, Gargiulo F, Manca N, Carosi G; RADAR-Master Study Group.

AIDS Patient Care STDS. 2007 Feb;21(2):92-9.

PMID:
17328658
14.

Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial.

Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P, Zorzi M, Confortini M, Cuzick J; New Technologies for Cervical Cancer screening Working Group.

Lancet Oncol. 2006 Jul;7(7):547-55.

PMID:
16814206
15.

Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.

Torti C, Uccelli MC, Quiros-Roldan E, Gargiulo F, Tirelli V, Lapadula G, Regazzi M, Pierotti P, Tinelli C, De Luca A, Patroni A, Manca N, Carosi G.

J Clin Virol. 2006 Apr;35(4):414-9. Epub 2005 Nov 8.

PMID:
16280255
16.

Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting.

Carozzi FM, Del Mistro A, Confortini M, Sani C, Puliti D, Trevisan R, De Marco L, Tos AG, Girlando S, Palma PD, Pellegrini A, Schiboni ML, Crucitti P, Pierotti P, Vignato A, Ronco G.

Am J Clin Pathol. 2005 Nov;124(5):716-21.

PMID:
16203283
17.

Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort.

Torti C, Maggiolo F, Patroni A, Suter F, Ladisa N, Paraninfo G, Pierotti P, Orani AM, Minoli L, Arici C, Sighinolfi L, Tinelli C, Carosi G; MASTER Cohort.

J Antimicrob Chemother. 2005 Jul;56(1):190-5. Epub 2005 May 25.

PMID:
15917286
18.

Distinct patterns of HIV-specific memory T lymphocytes in HIV-exposed uninfected individuals and in HIV-infected patients.

Schenal M, Lo Caputo S, Fasano F, Vichi F, Saresella M, Pierotti P, Villa ML, Mazzotta F, Trabattoni D, Clerici M.

AIDS. 2005 Apr 29;19(7):653-61.

PMID:
15821391
19.

HIV-1 subtypes and circulating recombinant forms (CRFs) from HIV-infected patients residing in two regions of central and southern Italy.

Monno L, Brindicci G, Lo Caputo S, Punzi G, Scarabaggio T, Riva C, Di Bari C, Pierotti P, Saracino A, Lagioia A, Mazzotta F, Balotta C, Angarano G.

J Med Virol. 2005 Apr;75(4):483-90.

PMID:
15714483
20.

Lopinavir plasma levels in salvage regimes by a population of highly active antiretroviral therapy-treated HIV-1-positive patients.

Torti C, Quiros-Roldan E, Tirelli V, Regazzi-Bonora M, Moretti F, Pierotti P, Orani A, Maggi P, Cargnel A, Patroni A, De Luca A, Carosi G; RADAR Study Group of the Master Cohort.

AIDS Patient Care STDS. 2004 Nov;18(11):629-34.

PMID:
15633260

Supplemental Content

Loading ...
Support Center